Hepatitis C Therapy

Consensus interferon may work when other regimens are ineffective

Published in Hepatitis Weekly, June 24th, 2002

by Sonia Nichols, senior medical writer - Genetically modified interferon (IFN), known as consensus interferon, may offer new hope to patients with chronic hepatitis C whose disease fails to respond to IFN and ribavirin combination therapy.

IFN and ribavirin combination therapy has become a mainstay for treating patients with chronic hepatitis C who are infected with hepatitis C virus (HCV) genotype 1. However, a fair number of patients who are prescribed combination therapy often won't demonstrate a sustained response when treatment ends, or after demonstrating a response, will relapse.

According to researchers in Rome, Italy, a genetically...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry